Business · 23/10/2002
FDA Announces OMB Approval for Postmarketing Adverse Drug Experience Reporting
The Food and Drug Administration (FDA) has announced that it has received approval from the Office of Management and Budget (OMB) to collect information on postmarketing adverse drug experiences under the Paperwork Reduction Act of 1995 (PRA).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →